Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB)

Historical Holders from Q3 2018 to Q3 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
YMAB
Shares outstanding
45,101,565
Price per share
$6.66
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
16,393
Total reported value
$78,346
% of total 13F portfolios
0%
Share change
-27,793,139
Value change
-$125,347,231
Number of holders
2
Price from insider filings
$6.66
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ACORN BIOVENTURES, L.P. 6.2% -11% $23,824,450 -$2,556,000 2,796,297 -9.7% Anders Hove 19 Aug 2025
As of 30 Sep 2025, Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) has 2 institutional shareholders filing 13F forms. They hold 16,393 shares. of 45,101,565 outstanding shares (0.04%) .

Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 16,393 $78,346 -$125,347,231 $6.66 2
2025 Q2 27,903,915 $125,848,990 -$3,989,587 $4.51 96
2025 Q1 28,806,277 $127,612,877 -$6,925,833 $4.43 102
2024 Q4 28,798,220 $225,491,693 -$942,929 $7.83 111
2024 Q3 25,737,929 $338,544,592 +$17,253,803 $13.15 105
2024 Q2 24,352,797 $294,183,301 +$14,884,656 $12.08 95
2024 Q1 22,993,565 $373,874,978 +$50,160,058 $16.26 94
2023 Q4 15,605 $106,426 -$257,717 $6.82 1
2023 Q3 19,680,958 $107,258,453 -$1,394,530 $5.45 98
2023 Q2 19,501,430 $132,413,047 +$4,779,046 $6.79 94
2023 Q1 19,046,569 $95,420,526 -$1,127,379 $5.01 83
2022 Q4 19,183,762 $93,613,950 -$55,179,912 $4.88 88
2022 Q3 23,069,268 $332,658,850 -$15,438,965 $14.42 90
2022 Q2 24,169,297 $365,670,143 -$5,519,297 $15.13 87
2022 Q1 21,920,374 $260,413,152 -$16,642,002 $11.88 83
2021 Q4 25,388,124 $411,464,701 -$18,341,542 $16.21 88
2021 Q3 26,193,080 $747,535,143 -$509,328 $28.54 95
2021 Q2 26,119,880 $886,036,617 -$1,162,536 $33.80 98
2021 Q1 26,322,684 $795,919,161 +$112,536,751 $30.24 115
2020 Q4 21,996,862 $1,089,082,954 +$38,075,131 $49.51 111
2020 Q3 21,209,185 $814,313,252 +$2,707,318 $38.39 102
2020 Q2 20,781,825 $897,805,408 +$48,749,465 $43.20 106
2020 Q1 19,999,261 $520,357,562 +$15,457,533 $26.10 77
2019 Q4 19,393,476 $606,044,157 +$185,369,544 $31.25 80
2019 Q3 13,103,652 $341,479,499 +$56,142,514 $26.06 63
2019 Q2 10,970,847 $250,881,874 +$54,307,704 $22.87 58
2019 Q1 8,468,051 $221,947,926 -$3,278,077 $26.21 43
2018 Q4 8,686,033 $175,686,000 +$18,726,280 $20.34 42
2018 Q3 7,733,371 $203,587,801 +$203,587,868 $26.56 38